Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer
- 14 January 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (2) , 513-523
Abstract
Purpose: Endometrioid endometrial carcinoma (EEC) is the major histologic type of endometrial cancer, the most prevalent gynecologic malignancy in the United States. EEC recurrence or metastasis is associated with a poor prognosis. Early-stage EEC is generally curable, but a subset has high risk of recurrence or metastasis. Prognosis estimation for early-stage EEC mainly relies on clinicopathologic characteristics, but is unreliable. We aimed to identify patients with high-risk early-stage EEC who are most likely to benefit from more extensive surgery and adjuvant therapy by building a prognostic model that integrates clinical variables and protein markers. Experimental Design: We used two large, independent early-stage EEC datasets as training (n = 183) and validation cohorts (n = 333), and generated the levels of 186 proteins and phosphoproteins using reverse-phase protein arrays. By applying an initial filtering and the elastic net to the training samples, we developed a prognostic model for overall survival containing two clinical variables and 18 protein markers and optimized the risk group classification. Results: The Kaplan–Meier survival analyses in the validation cohort confirmed an improved discriminating power of our prognostic model for patients with early-stage EEC over key clinical variables (log-rank test, P = 0.565 for disease stage, 0.567 for tumor grade, and 1.3 × 10−4 for the integrative model). Compared with clinical variables (stage, grade, and patient age), only the risk groups defined by the integrative model were consistently significant in both univariate and multivariate analyses across both cohorts. Conclusions: Our prognostic model is potentially of high clinical value for stratifying patients with early-stage EEC and improving their treatment strategies. Clin Cancer Res; 22(2); 513–23. ©2015 AACR.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Direct risk standardisation: a new method for comparing casemix adjusted event rates using complex modelsBMC Medical Research Methodology, 2013
- Predicting time to ovarian carcinoma recurrence using protein markersJournal of Clinical Investigation, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersClinical Proteomics, 2010
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationProceedings of the National Academy of Sciences, 2009
- HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancerBritish Journal of Cancer, 2008
- Carcinoma of the Corpus UteriInternational Journal of Gynecology & Obstetrics, 2006
- Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence FunctionBiometrics, 2005
- A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical stagingInternational Journal of Gynecological Cancer, 2004